What is the new generation painkiller? The rise of non-opioid solutions
•
4 min read
In a significant development for pain management, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) in early 2025, marking the first new class of pain medication in over two decades. This landmark approval raises a crucial question for patients and clinicians alike: **what is the new generation painkiller** and how will it reshape the future of treatment?
